Metformin and Longevity: Can a Diabetes Drug Slow Aging?

Introduction

Metformin has been a cornerstone of type 2 diabetes treatment for more than 60 years, prescribed to hundreds of millions of patients worldwide. Yet in recent years, scientists have turned their attention to a striking observation: some people with diabetes treated with metformin have been observed to outlive matched healthy controls who did not have diabetes. This paradox has sparked a wave of research into whether metformin can exert effects beyond glucose control — potentially slowing the biological process of aging itself.

This article is intended for general informational purposes and does not constitute medical advice or treatment recommendations. The use of metformin outside its approved indications is currently investigational.

Aging affects every organ system and is the primary risk factor for cardiovascular disease, cancer, dementia, and metabolic disorders. In the United States, age-related chronic diseases account for the majority of healthcare expenditure and disability. A drug that could meaningfully delay the onset of these conditions — even by a few years — would represent one of the most significant medical advances in history.

Biological Aging: Mechanisms and Hallmarks

Biological aging is not simply the passage of time — it is the cumulative result of cellular and molecular damage across a lifetime. Scientists have identified several key hallmarks of aging that drive disease and functional decline:

• Genomic instability: accumulating DNA damage from oxidative stress and imperfect repair.
• Telomere shortening: the protective caps on chromosomes erode with each cell division.
• Epigenetic alterations: chemical modifications to DNA and histones shift gene expression patterns in ways that promote aging.
• Cellular senescence: damaged cells stop dividing but remain metabolically active, secreting inflammatory signals that harm surrounding tissue.
• Inflammaging: a chronic, low-grade inflammatory state that accelerates tissue degeneration.
• Mitochondrial dysfunction: aging mitochondria produce less energy and more reactive oxygen species.
• Loss of protein homeostasis (proteostasis): the cell's ability to fold, repair, and clear proteins deteriorates.

Metformin's potential anti-aging value lies in its ability to intersect with several of these pathways simultaneously.

Metformin vs. Other Longevity Compounds

Diagnosis: Measuring Biological Age

There is currently no single clinical test to diagnose accelerated aging. Researchers use several approaches to measure biological age and detect aging-related changes:

Epigenetic clocks: DNA methylation patterns correlate closely with chronological age. The Horvath clock and other methylation-based tools estimate biological age and can detect deceleration in response to interventions.

Inflammatory biomarkers: elevated C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) signal inflammaging and elevated disease risk.

Telomere length: shorter telomeres are associated with accelerated biological aging, though variability is high across individuals.

Metabolic biomarkers: fasting glucose, HbA1c, insulin resistance indices, and lipid profiles reflect metabolic aging and are directly influenced by metformin.

Functional assessments: gait speed over 10 meters, grip strength, and cognitive testing are used in clinical trials such as TAME as primary outcome measures for functional aging.

Metformin as an Anti-Aging Intervention: Evidence

Preclinical evidence

Initial evidence came from model organisms. In the nematode Caenorhabditis elegans, metformin consistently extended lifespan. In mice, results were more variable — strain-specific differences significantly affected outcomes. A landmark 2024 study published in Cell found that metformin administered to aging male cynomolgus monkeys for more than three years slowed biological aging, with effects measurable across multiple organ systems and without substantial changes in body weight or routine laboratory parameters.

Human observational evidence

A widely cited UK study found that patients with type 2 diabetes treated with metformin had lower all-cause mortality than matched controls without diabetes who were not taking any anti-aging intervention. This counterintuitive finding — diabetic patients outsurviving healthy controls — was a major driver of scientific interest in metformin's geroprotective potential.

MILES trial (Metformin In Longevity Study)

This early clinical study in non-diabetic older adults found that short-term metformin treatment induced gene expression changes consistent with anti-aging transcriptional patterns, supporting the hypothesis that metformin alters aging biology even in people without diabetes.

TAME trial (Targeting Aging with Metformin)

The TAME trial, coordinated by Wake Forest University School of Medicine and supported by the American Federation for Aging Research (AFAR) and the NIH-funded Geroscience Network, is the first clinical trial designed to test whether a drug can delay aging as a primary endpoint. The design enrolls 3,000 non-diabetic adults aged 65–79 across 14 US research centers. Participants receive 1,500 mg of metformin daily for six years. Primary outcomes include the development of new age-related chronic diseases, changes in gait speed and cognition, and biomarkers of inflammation and cellular senescence.

Conflicting evidence

The 2025 MET-PREVENT trial found that four months of metformin treatment did not improve grip strength, walking speed, physical performance, muscle mass, or quality of life in older adults. A 2025 ScienceDirect review noted that evidence for metformin as a geroprotector remains mixed, particularly in non-diabetic populations. Scientific debate continues, and TAME results will be critical to resolving current uncertainty.

Mechanisms: How Metformin May Influence Aging

Metformin enters cells primarily via the organic cation transporter 1 (OCT1) and exerts its effects through several converging pathways:

1. AMPK activation Metformin partially inhibits Complex I of the mitochondrial electron transport chain, raising the AMP/ATP ratio. This activates AMP-activated protein kinase (AMPK), a master energy sensor that promotes metabolic efficiency, suppresses inflammatory signaling, and inhibits mTOR.

2. mTOR inhibition By dampening the mechanistic target of rapamycin (mTOR) pathway — a key driver of cellular growth and a known aging accelerator — metformin promotes a cellular state associated with longevity. Reduced mTOR activity encourages autophagy: the cell's self-cleaning process that removes damaged proteins and organelles.

3. Reduction of cellular senescence Research published in Nature Aging (2026) showed that metformin inhibits nuclear egress of chromatin fragments, a mechanism by which senescent cells trigger systemic inflammation. By blocking this pathway via AMPK, metformin may reduce the inflammatory burden of senescent cells.

4. Epigenetic protection Metformin modulates DNA methylation and histone modification patterns, potentially stabilizing the epigenetic landscape and slowing epigenetic clock progression.

5. Vitamin B12 consideration Chronic metformin use impairs vitamin B12 absorption in 6–30% of long-term users. B12 deficiency causes neurological symptoms, fatigue, and anemia. Monitoring B12 levels annually is recommended for anyone on long-term metformin.

Warning Signs: When Metformin Is Not Appropriate

Metformin has a well-established safety record, but certain conditions require caution or contraindication:

• Kidney impairment (estimated glomerular filtration rate below 30 mL/min/1.73m²): metformin is contraindicated due to risk of lactic acidosis.
• Severe liver disease: impairs metformin clearance.
• Contrast dye procedures: metformin should be temporarily held before and after intravenous iodinated contrast in patients with kidney risk.
• Alcohol overuse: increases lactic acidosis risk.
• Surgical procedures requiring fasting: metformin should typically be held.

Seek immediate care if you experience: • Severe muscle pain, weakness, or cramps • Difficulty breathing or rapid breathing • Unusual fatigue with nausea and vomiting • Numbness or tingling in hands and feet (possible B12 deficiency)

When to See a Doctor

• Before starting metformin for any purpose: a physician must assess kidney function, liver status, and medication interactions.
• If you are considering metformin for longevity or anti-aging purposes outside an approved clinical trial: discuss realistic expectations, the current state of evidence, and monitoring requirements with a clinician experienced in geroscience or preventive medicine.
• If you develop any gastrointestinal side effects (nausea, diarrhea): most resolve with dose titration, but persistent symptoms require evaluation.
• For annual monitoring of B12 levels and kidney function in any person on long-term metformin.

Practical Tips

• Do not self-prescribe metformin for anti-aging: it remains unapproved for this indication. Clinical trials are the appropriate setting.
• If you have type 2 diabetes and take metformin: monitor B12 annually and discuss your cardiovascular and longevity profile with your clinician.
• Stay informed about TAME trial progress: results will substantially clarify whether metformin delays aging in non-diabetic adults.
• Combine pharmacological and lifestyle approaches: caloric restriction, regular aerobic exercise, quality sleep, and stress management activate many of the same AMPK and autophagy pathways that metformin targets.
• Extended-release formulations reduce gastrointestinal side effects and may improve tolerability for long-term use.

FAQ

What is metformin used for?

Metformin is primarily approved by the FDA as a first-line oral medication for the management of type 2 diabetes mellitus. It works by decreasing hepatic glucose production, improving insulin sensitivity in peripheral tissues, and mildly reducing glucose absorption in the gut. It is also used off-label in polycystic ovary syndrome (PCOS) to improve insulin sensitivity and restore ovulation. In recent years, researchers have investigated metformin as a potential anti-aging compound — a use that remains investigational and is not currently an approved indication anywhere in the world.

What does metformin do?

Metformin's primary action is to lower blood glucose levels without causing insulin secretion directly, which means it rarely causes hypoglycemia when used alone. At the cellular level, it partially inhibits Complex I of the mitochondrial electron transport chain, raising intracellular AMP levels and activating AMPK. This triggers a cascade: mTOR is suppressed, autophagy is stimulated, inflammatory signaling decreases, and epigenetic stability may improve. These downstream effects — particularly AMPK activation and mTOR inhibition — overlap with biological pathways associated with longevity in multiple species, which is why the drug has attracted significant geroscience interest.

Can metformin slow aging in humans who do not have diabetes?

The honest answer as of 2026 is: possibly, but not yet proven. Animal evidence — particularly a 2024 Cell study in cynomolgus monkeys — is compelling. Human observational data suggests diabetic patients on metformin outlive matched healthy controls, a counterintuitive finding that points to a potentially meaningful biological effect. However, controlled trial data in non-diabetic humans is limited, mixed, and inconclusive. The 2025 MET-PREVENT trial found no improvement in physical function or quality of life after four months. The TAME trial — the definitive six-year human study — is still underway and has not yet reported outcomes. Current consensus: metformin is promising but not proven as a longevity drug.

What is the TAME trial and when will results be available?

TAME (Targeting Aging with Metformin) is a landmark multi-center, randomized, double-blind, placebo-controlled clinical trial coordinated by Wake Forest University School of Medicine and funded in part by the American Federation for Aging Research and ARPA-H. It enrolls 3,000 non-diabetic adults aged 65–79, administering 1,500 mg of metformin daily for six years. Primary endpoints include development of new age-related diseases, gait speed, cognition, and aging biomarkers. TAME is designed not only to test metformin but to establish a regulatory framework for future anti-aging drug approvals at the FDA. The trial has faced partial funding challenges. Full results are not expected before the late 2020s.

Summary

Metformin's potential as an anti-aging compound rests on decades of biological plausibility, robust animal data, compelling human observational findings, and early mechanistic studies. Its ability to activate AMPK, inhibit mTOR, reduce cellular senescence, and modulate epigenetic patterns aligns with multiple hallmarks of biological aging. The TAME trial represents a historic effort to bring this evidence to a definitive clinical test in humans.

At the same time, caution is warranted. The MET-PREVENT trial did not show functional anti-aging benefits after short-term use, and the overall evidence in non-diabetic populations remains mixed. For patients with type 2 diabetes, metformin remains an excellent, evidence-based first-line treatment with potential added benefits. For those without diabetes, metformin use for longevity is not currently supported by guidelines and should only be considered in the context of a clinical trial or under careful physician supervision. Research in this field continues to evolve — TAME results will likely be decisive.

References

1. Mohammed I, Hollenberg MD, Ding H, Triggle CR. A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan. Front Endocrinol (Lausanne). 2021;12:718942. Source: pmc.ncbi.nlm.nih.gov
2. American Federation for Aging Research. TAME — Targeting Aging with Metformin Trial. Source: www.afar.org
3. Gu M, Zheng A, Tu W, et al. The Anti-Aging Mechanism of Metformin: From Molecular Insights to Clinical Applications. Molecules. 2025;30(4):816. Source: pmc.ncbi.nlm.nih.gov
4. Chen J, Ou Y, Li Y, et al. Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. Theranostics. 2022;12(6):2722-2740. Source: www.thno.org
5. Abou Zaki R, El-Osta A. Metformin: decelerates biomarkers of aging clocks. Signal Transduct Target Ther. 2024;9:319. Source: www.nature.com
6. Emerging uncertainty on the anti-aging potential of metformin. ScienceDirect. 2025. Source: www.sciencedirect.com
7. Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471(3):307-322. Source: www.ncbi.nlm.nih.gov
8. Metformin treatment of diverse Caenorhabditis species reveals the importance of genetic background. PMC. 2022. Source: www.ncbi.nlm.nih.gov
9. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab. 2016;23(6):1060-1065. Source: pubmed.ncbi.nlm.nih.gov
10. Witham MD, et al. MET-PREVENT trial: Metformin in older adults with physical frailty (2025). Ageing Cell.
11. Yang Y, et al. Metformin decelerates aging clock in male monkeys. Cell. 2024;187:6358-6378. Source: pubmed.ncbi.nlm.nih.gov
12. Kumazawa M, et al. Metformin inhibits nuclear egress of chromatin fragments in senescence and aging. Nature Aging. 2026. Source: www.nature.com
13. Lifespan.io. Nir Barzilai: Positive Evidence for Metformin is Mounting. August 2025. Source: lifespan.io
14. Metformin Beyond Diabetes: A Precision Gerotherapeutic and Immunometabolic Adjuvant for Aging and Cancer. Cancers. 2025. Source: www.mdpi.com

Key Takeaways

• Metformin is a 60-year-old diabetes drug now being studied as a potential anti-aging compound.
• Its primary anti-aging mechanisms involve activating AMPK, inhibiting mTOR, stimulating autophagy, and reducing cellular senescence.
• Observational evidence shows diabetic patients on metformin sometimes outlive matched healthy controls — a paradox that drives longevity research.
• The TAME trial is the first clinical trial designed to establish whether a drug can delay aging itself, enrolling 3,000 non-diabetic adults aged 65–79.
• A 2024 Cell study found metformin slowed biological aging in cynomolgus monkeys over three years.
• The 2025 MET-PREVENT trial found no functional improvement in older adults after short-term metformin use, highlighting ongoing uncertainty.
• Metformin is not approved for anti-aging use and should not be self-prescribed for this purpose.
• Long-term metformin use causes vitamin B12 deficiency in 6–30% of users — annual monitoring is essential.
• The TAME trial results, expected in the late 2020s, will likely determine whether metformin earns a role in geroscience treatment protocols.

Medical Disclaimer

This article is intended for general information only and does not constitute medical advice, diagnosis, or treatment recommendations. It is not a substitute for consultation with a qualified healthcare professional. Information is based on scientific evidence as of June 2026.

Before starting, stopping, or changing any medication, supplement, or therapy, consult a clinician familiar with your full medical history.

In a medical emergency, seek immediate care. US: 911 · Europe: 112 · Israel: 101. Do not rely on internet information in an emergency.